ES2033429T3 - Un metodo de preparacion de una composicion farmaceutica. - Google Patents
Un metodo de preparacion de una composicion farmaceutica.Info
- Publication number
- ES2033429T3 ES2033429T3 ES198888305138T ES88305138T ES2033429T3 ES 2033429 T3 ES2033429 T3 ES 2033429T3 ES 198888305138 T ES198888305138 T ES 198888305138T ES 88305138 T ES88305138 T ES 88305138T ES 2033429 T3 ES2033429 T3 ES 2033429T3
- Authority
- ES
- Spain
- Prior art keywords
- preparing
- pharmaceutical composition
- cyclosporins
- cyclodextrin
- fungal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 abstract 1
- 108010036941 Cyclosporins Proteins 0.000 abstract 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 abstract 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000003429 antifungal agent Substances 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14070387 | 1987-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2033429T3 true ES2033429T3 (es) | 1993-03-16 |
Family
ID=15274767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES198888305138T Expired - Lifetime ES2033429T3 (es) | 1987-06-04 | 1988-06-06 | Un metodo de preparacion de una composicion farmaceutica. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5051402A (enExample) |
| EP (1) | EP0294239B1 (enExample) |
| JP (1) | JP2577049B2 (enExample) |
| AT (1) | ATE72629T1 (enExample) |
| AU (1) | AU607506B2 (enExample) |
| CA (1) | CA1325973C (enExample) |
| DE (1) | DE3868438D1 (enExample) |
| ES (1) | ES2033429T3 (enExample) |
| GR (1) | GR3004199T3 (enExample) |
| HK (1) | HK28097A (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| JPH07111785B2 (ja) | 1990-01-19 | 1995-11-29 | 富士通株式会社 | 光ディスク |
| US5227372A (en) * | 1990-03-07 | 1993-07-13 | Children's Medical Center Corporation | Method for retaining ophthalmological agents in ocular tissues |
| HU208491B (en) * | 1990-11-27 | 1993-11-29 | Gyogyszerkutato Intezet | Process for producing oral pharmaceutical composition containing cyclosporin |
| FR2670629B1 (fr) * | 1990-12-17 | 1995-03-10 | Moving Magnet Tech | Actionneur electromagnetique monophase rotatif. |
| DE69222150T2 (de) * | 1991-01-25 | 1998-01-15 | Fujisawa Pharmaceutical Co | Prozess zur produktion von cyclosporin-a und/oder c |
| SG45449A1 (en) * | 1992-05-13 | 1998-01-16 | Sandoz Ltd | Ophthalmic compositions |
| US5494901A (en) * | 1993-01-05 | 1996-02-27 | Javitt; Jonathan C. | Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent |
| NZ247516A (en) * | 1993-04-28 | 1995-02-24 | Bernard Charles Sherman | Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant |
| US5474979A (en) * | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| WO1995032726A1 (en) * | 1994-06-01 | 1995-12-07 | Yuhan Corporation | Cyclosporin containing composition and process for the preparation thereof |
| KR0167613B1 (ko) * | 1994-12-28 | 1999-01-15 | 한스 루돌프 하우스, 니콜 케르커 | 사이클로스포린-함유 연질캅셀제 조성물 |
| JP2007056045A (ja) * | 1995-05-26 | 2007-03-08 | Nobaruteisu Fuaama Kk | サイクロデキストリン組成物 |
| JP3934705B2 (ja) * | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
| US5827822A (en) * | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
| US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
| US5766629A (en) * | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US20070185032A1 (en) * | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US5968895A (en) * | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| PT988046E (pt) * | 1997-01-30 | 2004-12-31 | Novartis Ag | Composicoes farmaceuticas sem oleo contendo ciclosporina a |
| NZ328751A (en) | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
| DE69832984T2 (de) | 1997-10-08 | 2006-09-21 | Isotechnika, Inc., Edmonton | DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN |
| US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| TW581681B (en) * | 1998-02-20 | 2004-04-01 | Nektar Therapeutics | Liquid crystal forms of cyclosporin |
| US20040152664A1 (en) * | 1998-09-02 | 2004-08-05 | Allergan, Inc. | Prednisolone compositions |
| WO2000012137A1 (en) * | 1998-09-02 | 2000-03-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| EP1435910B9 (en) * | 2001-10-19 | 2010-02-03 | Isotechnika Inc. | Novel cyclosporin analog microemulsion preconcentrates |
| HRP20070058B1 (hr) | 2001-10-19 | 2014-05-23 | Isotechnika Inc. | Sinteza ciklosporinskih analoga |
| US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| US20050112087A1 (en) * | 2003-04-29 | 2005-05-26 | Musso Gary F. | Pharmaceutical formulations for sustained drug delivery |
| US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
| JP2007512337A (ja) | 2003-11-21 | 2007-05-17 | コンビナトアールエックス インコーポレーティッド | 炎症性障害の治療のための方法および試薬 |
| US7691812B2 (en) * | 2004-11-04 | 2010-04-06 | Trustees Of The University Of Pennsylvania | Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine A or other cyclophilin inhibitors |
| US7288520B2 (en) * | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
| US7297679B2 (en) * | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
| US20070015691A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| US7202209B2 (en) | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
| US7276476B2 (en) * | 2005-07-13 | 2007-10-02 | Allergan, Inc. | Cyclosporin compositions |
| US20070015693A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| WO2007011880A2 (en) | 2005-07-18 | 2007-01-25 | Minu, L.L.C. | Enhanced ocular neuroprotection/neurostimulation |
| US7501393B2 (en) | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
| US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
| US8067433B2 (en) | 2005-11-09 | 2011-11-29 | Zalicus Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
| DE102006051512A1 (de) | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
| FI118537B (fi) * | 2006-03-08 | 2007-12-14 | Kuopion Yliopisto | Menetelmä syklodekstriinin kompleksoitumisen lisäämiseksi |
| US9561178B2 (en) * | 2006-07-25 | 2017-02-07 | Allergan, Inc. | Cyclosporin compositions |
| US20080146497A1 (en) * | 2006-07-25 | 2008-06-19 | Graham Richard S | Cyclosporin Compositions |
| AU2016203191B2 (en) * | 2006-07-25 | 2018-03-01 | Allergan, Inc. | Cyclosporin compositions |
| CN101896160A (zh) * | 2006-10-17 | 2010-11-24 | 阿勒根公司 | 环胞菌素组合物 |
| JP5668476B2 (ja) | 2007-10-08 | 2015-02-12 | オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物 |
| US20100016219A1 (en) * | 2008-07-19 | 2010-01-21 | Jerry Zhang | Ophthalmic compositions containing solubilized cyclosporin |
| EP2440185B1 (en) | 2009-06-09 | 2015-04-08 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
| KR20140054005A (ko) * | 2011-06-29 | 2014-05-08 | 알러간, 인코포레이티드 | 마크로골 15 하이드록시스테아레이트 제형 |
| AU2016272700A1 (en) * | 2015-05-29 | 2017-12-14 | Oculis ehf. | Formation of cyclosporin A/cyclodextrin nanoparticles |
| CN105997863B (zh) * | 2016-07-21 | 2018-09-04 | 河南省眼科研究所 | 环孢素a滴眼液及其制备方法 |
| PT3548091T (pt) | 2016-11-29 | 2022-01-21 | Oculis SA | Preparação de complexos sólidos de ciclodextrina para administração oftálmica de ingrediente farmacêutico ativo |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| WO2021001366A1 (en) | 2019-07-01 | 2021-01-07 | Oculis SA | Method for stabilizing the ph of an aqueous composition comprising a drug |
| CN112724200B (zh) * | 2019-10-28 | 2022-09-27 | 上海云泽生物科技有限公司 | 一种稳定环孢霉素a的稀释液及其应用 |
| CN116390762B (zh) | 2020-11-09 | 2026-05-08 | 思凯制药有限公司 | 固体环孢菌素a和包含其的分散组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117118A (en) * | 1976-04-09 | 1978-09-26 | Sandoz Ltd. | Organic compounds |
| FI65914C (fi) * | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
| AU558155B2 (en) * | 1982-02-01 | 1987-01-22 | Sandoz Ltd. | Treating multiple sclerosis with dihydro-cyclosporin d |
| EP0094157B1 (en) * | 1982-04-30 | 1987-07-29 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its use |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| DE3580717D1 (de) * | 1984-08-02 | 1991-01-10 | Sandoz Ag | Pharmazeutische anwendung von (nva)2-cyclosporine. |
-
1988
- 1988-06-02 JP JP63136250A patent/JP2577049B2/ja not_active Expired - Lifetime
- 1988-06-03 AU AU17386/88A patent/AU607506B2/en not_active Expired
- 1988-06-06 CA CA000568734A patent/CA1325973C/en not_active Expired - Lifetime
- 1988-06-06 DE DE8888305138T patent/DE3868438D1/de not_active Expired - Lifetime
- 1988-06-06 ES ES198888305138T patent/ES2033429T3/es not_active Expired - Lifetime
- 1988-06-06 AT AT88305138T patent/ATE72629T1/de not_active IP Right Cessation
- 1988-06-06 EP EP88305138A patent/EP0294239B1/en not_active Expired - Lifetime
-
1990
- 1990-09-21 US US07/587,580 patent/US5051402A/en not_active Expired - Lifetime
-
1992
- 1992-03-31 GR GR920400570T patent/GR3004199T3/el unknown
-
1997
- 1997-03-06 HK HK28097A patent/HK28097A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6485921A (en) | 1989-03-30 |
| CA1325973C (en) | 1994-01-11 |
| DE3868438D1 (de) | 1992-03-26 |
| JP2577049B2 (ja) | 1997-01-29 |
| EP0294239B1 (en) | 1992-02-19 |
| EP0294239A1 (en) | 1988-12-07 |
| HK28097A (en) | 1997-03-06 |
| US5051402A (en) | 1991-09-24 |
| AU607506B2 (en) | 1991-03-07 |
| AU1738688A (en) | 1988-12-22 |
| GR3004199T3 (enExample) | 1993-03-31 |
| ATE72629T1 (de) | 1992-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3004199T3 (enExample) | ||
| PT88417A (pt) | Stabilisierte humanprotein-praeparate | |
| ATE109002T1 (de) | Wasserlösliche antineoplastische taxolderivate. | |
| MY102660A (en) | Therapeutic system for sparingly soluble active ingredients | |
| DE58906926D1 (de) | Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung. | |
| SE9503143D0 (sv) | New preparation | |
| ES2062206T3 (es) | Composicion estabilizada de fgf y su produccion. | |
| DE59310197D1 (de) | Lagerstabile wässrige pharmazeutische zubereitungen von g-csf | |
| ES2065906T3 (es) | Produccion de proteinas en formas activas. | |
| WO1991015512A3 (en) | Hiv envelope polypeptides | |
| SE8804628D0 (sv) | New compounds | |
| DE3776620D1 (de) | 3-propenylcephemderivate, ihre herstellung, zwischenverbindungen, pharmazeutische praeparate und anwendung. | |
| EP0230264A3 (en) | Pharmaceutical composition for nasal application, process for its preparation and its use | |
| ATE168115T1 (de) | In lösung bringen von proteinen in aktiver form | |
| ATE70445T1 (de) | Pharmazeutische praeparate. | |
| IT8819958A0 (it) | Derivati alchiltiobenzimidazolici attivi farmacologicamente eprocedimento per la loro preparazione. | |
| KR900007816A (ko) | 사이클로프로필-치환된 아졸릴메틸카비놀, 이의 제조방법 및 약제로서의 이의 용도 | |
| RU96106437A (ru) | Способ лечения сухой остаточной полости после перенесенного абсцесса легкого | |
| DE3774849D1 (de) | Alkylaminoalkylisch oder heterocyclylalkylisch an den triazolring substituierte 8-azaxanthine, ihre physiologisch vertraeglichen salze, ihre pharmazeutische zubereitungen mit antibronchospastischer wirkung und verfahren zu ihrer herstellung. | |
| FR2572932B1 (fr) | Medicament insoluble administre localement dans l'oreille | |
| PT968717E (pt) | Preparacao sob a forma galenica simples visando limitar os efeitos ocorridos durante a menopausa, e posteriormente, e tratamento com esta preparacao | |
| IT8819959A0 (it) | Derivati alcossibenzimidazolici farmacologicamente attivi eprocedimento di preparazione. | |
| IT1203917B (it) | Farmacologicamente attivi. derivati dell'1,2,4-triazolo | |
| IT8620504A0 (it) | Derivati dell'1,2,4-triazolo farmacologicamente attivi. | |
| NO862740D0 (no) | Fremgangsmaate for stabilisering av xantangummi i vandig loesning. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 294239 Country of ref document: ES |